---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Androgen receptor pathway inhibitors"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Androgen receptor pathway inhibitors. Topics: Enzalutamide: FDA-approved indications, Abiraterone acetate: FDA-approved indications, Apalutamide: FDA-approved indications, Darolutamide: FDA-approved indications, and 8 further topics. 12 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/androgen-receptor-pathway-inhibitors"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Androgen receptor pathway inhibitors

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Androgen Receptor Pathway Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

### Enzalutamide: FDA-approved indications

> “XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:”
> “castration-resistant prostate cancer (CRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC)”

Source: [Xtandi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/203415s026lbl.pdf)

<a id="topic-2.2.2.1.2-2"></a>

### Abiraterone acetate: FDA-approved indications

> “ZYTIGA is indicated in combination with prednisone for the treatment of patients with”
> “Metastatic castration-resistant prostate cancer (CRPC)”
> “Metastatic high-risk castration-sensitive prostate cancer (CSPC)”

Source: [Zytiga prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202379s035lbl.pdf)

<a id="topic-2.2.2.1.2-3"></a>

### Apalutamide: FDA-approved indications

> “ERLEADA is indicated for the treatment of patients with”
> “Metastatic castration-sensitive prostate cancer (mCSPC)”
> “Non-metastatic castration-resistant prostate cancer (nmCRPC)”

Source: [Erleada prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210951s024lbl.pdf)

<a id="topic-2.2.2.1.2-4"></a>

### Darolutamide: FDA-approved indications

> “NUBEQA is indicated for the treatment of adult patients with:”
> “non-metastatic castration resistant prostate cancer (nmCRPC)”
> “metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.”

Source: [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf)

<a id="topic-2.2.2.1.2-5"></a>

### Guideline statements on sequencing androgen receptor pathway inhibitors

> “In general, sequencing of ARPIs like abiraterone and enzalutamide is not recommended particularly if the time of response to ADT and to the first ARPI was short (≤ six to twelve months) and high-risk features of rapid progression are present”
> “This cross resistance with abiraterone should also be extrapolated to apalutamide and darolutamide.”
> “Also, the sequential use of the lutamides (apalutamide, darolutamide, enzalutamide) is not recommended as the mode of action is very similar.”
> “Avoid sequencing of androgen receptor-targeted agents.”

Source: [EAU (2026)](https://uroweb.org/guidelines/prostate-cancer/chapter/treatment)

<a id="topic-2.2.2.1.2-6"></a>

### Absence of comparative sequencing trials

> “Because there are no head-to-head comparisons, there are no trials to help decide which of these agents should be used first or in what sequence they should be used.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.2-7"></a>

### Randomized crossover trial of abiraterone and enzalutamide sequences

> “Primary endpoints were time to second PSA progression and PSA response (≥30% decline from baseline) on second-line therapy, analysed by intention-to-treat in all randomly assigned patients and in patients who crossed over, respectively.”
> “PSA responses to second-line therapy were seen in 26 (36%) of 73 patients for enzalutamide and three (4%) of 75 for abiraterone (χ2 p<0·0001).”
> “Enzalutamide showed activity as a second-line novel androgen receptor pathway inhibitor, whereas abiraterone acetate did not, leading to a longer time to second PSA progression for the sequence of abiraterone followed by enzalutamide than with the opposite treatment sequence.”

Source: [Khalaf et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31727538/)

<a id="topic-2.2.2.1.2-8"></a>

### Single-arm study of enzalutamide after abiraterone

> “Multicentre, single-arm, open-label study, enrolled patients with progressing mCRPC after ≥24 wk of abiraterone acetate plus prednisone treatment.”
> “Median radiographic progression-free survival was 8.1 mo (95% confidence interval: 6.1-8.3); median overall survival had not been reached.”
> “Unconfirmed PSA response rate was 27% (48 of 181).”
> “Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.”

Source: [de Bono et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28844372/)

<a id="topic-2.2.2.1.2-9"></a>

### Adding enzalutamide to abiraterone at PSA progression on enzalutamide: PLATO

> “Median progression-free survival was 5.7 months in the combination group and 5.6 months in the control group (hazard ratio, 0.83; 95% CI, 0.61 to 1.12; P = .22).”
> “PLATO also reported limited benefit with abiraterone after enzalutamide.”
> “Overall, results from PLATO suggest that enzalutamide should not be continued in combination with abiraterone after PSA progression during enzalutamide monotherapy.”

Source: [Attard et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6118405/)

<a id="topic-2.2.2.1.2-10"></a>

### Second inhibitor after docetaxel and one inhibitor: CARD control arm

> “The median imaging-based progression-free survival was 8.0 months with cabazitaxel and 3.7 months with the androgen-signaling-targeted inhibitor.”
> “The median overall survival was 13.6 months with cabazitaxel and 11.0 months with the androgen-signaling-targeted inhibitor (hazard ratio for death, 0.64; 95% CI, 0.46 to 0.89; P = 0.008).”
> “a prostate-specific antigen response occurred in 35.7% and 13.5% of the patients, respectively (P<0.001)”

Source: [de Wit et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31566937/)

<a id="topic-2.2.2.1.2-11"></a>

### Change of inhibitor in taxane-naive disease: PSMAfore control arm

> “Eligible patients were adults with PSMA-positive mCRPC who were candidates for a change of ARPI following one instance of disease progression on abiraterone, enzalutamide, darolutamide, or apalutamide as their most recent anticancer therapy.”
> “At third data cut-off after 334 rPFS events, the updated hazard ratio for radiographic progression or death with 177 Lu-PSMA-617 vs ARPI change was 0·49 (95% CI, 0·39–0·61); the median rPFS was 11·60 months (95% CI, 9·30–14·19) vs 5·59 months (4·21–5·95)”
> “At third data cut-off, the proportion of patients with confirmed prostate-specific antigen (PSA) decline of at least 50% from baseline was higher with 177 Lu-PSMA-617 vs ARPI change (51% [95% CI, 43·8–57·5] vs 17% [12·6–22·9])”
> “In the ARPI change group, the median duration of exposure was 6·52 months (IQR, 7·77); 100 patients received abiraterone and 132 patients received enzalutamide.”

Source: [Morris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12121614/)

<a id="topic-2.2.2.1.2-12"></a>

### Second inhibitor as control in BRCA-altered disease: TRITON3

> “the median duration was also longer with rucaparib than with abiraterone acetate or enzalutamide (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% CI, 0.25 to 0.58)”

Source: [Fizazi et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10064172/)

Additional sources: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Fizazi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41679466/); [NCCN (2026)](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
